Study: Drug combo heals hepatitis C in 93% of patients

HealthDay reports that researchers at Duke University have published a study in JAMA showing that a combination of daclatasvir, asunaprevir, and beclabuvir “effectively cleared the [hepatitis C] virus in 93 percent of patients.” The piece says the study, funded by Bristol-Myers Squibb, “involved 112 patients with cirrhosis related to hepatitis C that were never treated, as well as 90 who had undergone unsuccessful treatment for the condition.”

Duke University noted in a press release that the FDA has not approved any of the drugs used in the research, but it is currently reviewing daclatasvir.

The Medical Daily also reports, adding that the drug combination “came free of severe side effects.”

Enter your email to subscribe to Dr. Walt's blogs.

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

Dr. Walt Larimore will use the information you provide on this form to be in touch with you and to provide updates and marketing.